A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
Author:
Funder
3SBio Inc
Publisher
Elsevier BV
Subject
Molecular Biology,Immunology
Reference50 articles.
1. Cancer Facts & Figures;American Cancer Society,2018
2. Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries;Zeng;J. Thorac. Dis.,2014
3. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities;Yarden;Eur. J. Cancer,2001
4. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research;Earp;Breast Cancer Res. Treat.,1995
5. Targeted therapy in breast Cancer The HER-2/neu gene and protein;Ross;Mol. Cell. Proteom.,2004
Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11
2. Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer;MedComm;2024-04-29
3. In Silico Analysis of Novel Bacterial Metabolites with Anticancer Activities;Metabolites;2024-03-13
4. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02
5. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial;Cancer Pathogenesis and Therapy;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3